Drug treatment strategies for secondary diabetes in patients with acromegaly

References

• Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119:3189–3202.
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary. 1999;2:29–41.
   PubMedGoogle Scholar
• Lavrentaki A, Paluzzi A, Wass JAH, et al. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20:4–9.
   PubMed Web of Science ®Google Scholar
• Reid TJ, Post KD, Bruce JN, et al. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf). 2010;72:203–208.
   PubMed Web of Science ®Google Scholar
• Kreitschmann-Andermahr I, Siegel S, Kleist B, et al. Diagnosis and management of acromegaly: the patient’s perspective. Pituitary. 2016;19:268–276.
   PubMed Web of Science ®Google Scholar
• Abreu A, Tovar AP, Castellanos R, et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary. 2016;19:448–457.
   PubMed Web of Science ®Google Scholar
• Katznelson L. Approach to the patient with persistent acromegaly after pituitary surgery. J Clin Endocrinol Metab. 2010;95:4114–4123.
   PubMed Web of Science ®Google Scholar
• Pivonello R, Auriemma RS, Grasso LFS, et al. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary. 2017;20:46–62.
   PubMed Web of Science ®Google Scholar
• Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25:102–152.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Kasuki L, Lim DST, et al. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019;40:268–332.
   PubMed Web of Science ®Google Scholar
• Donnelly DE, Morrison PJ. Hereditary Gigantism-the biblical giant Goliath and his brothers. Ulster Med J. 2014;83:86–88.
   PubMedGoogle Scholar
• Galassi FM, Henneberg M, de Herder W, et al. Oldest case of gigantism? Assessment of the alleged remains of Sa-Nakht, king of ancient Egypt. Lancet Diabetes Endocrinol. 2017;5:580–581.
   PubMed Web of Science ®Google Scholar
• de Herder WW. The history of acromegaly. Neuroendocrinology. 2015;61:238–252.
   Google Scholar
• Marie P. Acromegaly. Brain. 1889;12:59–81.
   Google Scholar
• Health P. Poor-law medical services. BMJ. 1890;2:252–253.
   Google Scholar
• Davidoff LM. Studies in acromegaly iii. The anamnesis and symptomatology in one hundred cases. Endocrinology. 1926;10:461–483.
   Google Scholar
• Colwell AR. The relation of the hypophysis to diabetes mellitus. Medicine (Baltimore). 1927;6:1–39.
   Google Scholar
• John HJ. The possible relationship between acromegaly and diabetes. Arch Intern Med. 1926;37:489.
   Google Scholar
• Mestrón A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur J Endocrinol. 2004;151:439–446.
   PubMed Web of Science ®Google Scholar
• Fieffe S, Morange I, Petrossians P, et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol. 2011;164:877–884.
   PubMed Web of Science ®Google Scholar
• Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, et al. The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab. 2016;101:3997–4004.
   PubMed Web of Science ®Google Scholar
• Petrossians P, Daly AF, Natchev E, et al. Acromegaly at diagnosis in 3173 patients from the liège acromegaly survey (LAS) database. Endocr Relat Cancer. 2017;24:505–518.
   PubMed Web of Science ®Google Scholar
• Arosio M, Reimondo G, Malchiodi E, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012;167:189–198.
   PubMed Web of Science ®Google Scholar
• Stelmachowska-Banaś M, Zdunowski P, Zgliczyński W. Abnormalities in glucose homeostasis in acromegaly. Does the prevalence of glucose intolerance depend on the level of activity of the disease and the duration of the symptoms? Endokrynol Pol. 2009;60:20–24.
   PubMed Web of Science ®Google Scholar
• Vitale G, Pivonello R, Auriemma RS, et al. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf). 2005;63:470–476.
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Galdiero M, et al. Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab. 2009;94:528–537.
   PubMed Web of Science ®Google Scholar
• Biering H, Knappe G, Gerl H, et al. Diabetes-Häufigkeit bei Akromegalie und Cushing-Syndrom. Acta Med Austriaca. 2000;27:27–31.
   PubMedGoogle Scholar
• Alexopoulou O, Bex M, Kamenicky P, et al. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary. 2014;17:81–89.
   PubMed Web of Science ®Google Scholar
• Niculescu D, Purice M, Coculescu M. Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly. Pituitary. 2013;16:168–174.
   PubMed Web of Science ®Google Scholar
• Ciresi A, Amato MC, Pivonello R, et al. The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab. 2013;98:E51–59.
   PubMed Web of Science ®Google Scholar
• Espinosa-de-los-Monteros AL, González B, Vargas G, et al. Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary. 2011;14:231–235.
   PubMed Web of Science ®Google Scholar
• Solari D, Pivonello R, Caggiano C, et al. Pituitary adenomas: what are the key features? What are the current treatments? Where is the future taking us? World Neurosurg. 2019;127:695–709.
   PubMed Web of Science ®Google Scholar
• Altuntaş SÇ, Evran M, Sert M, et al. Markers of metabolic syndrome in patients with pituitary adenoma: a case series of 303 patients. Horm Metab Res. 2019;51:709–713.
   PubMed Web of Science ®Google Scholar
• Rosario PW. Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population. Pituitary. 2011;14:217–221.
   PubMed Web of Science ®Google Scholar
• Suda K, Fukuoka H, Iguchi G, et al. The prevalence of acromegaly in hospitalized patients with type 2 diabetes. Endocr J. 2015;62:53–59.
   PubMed Web of Science ®Google Scholar
• Boguszewski CL, Boguszewski MCDS, de Herder WW. From dwarves to giants: south American’s contribution to the history of growth hormone and related disorders. Growth Horm IGF Res. 2020;50:48–56.
   PubMed Web of Science ®Google Scholar
• Lindholm J. Growth hormone: historical notes. Pituitary. 2006;9:5–10.
   PubMedGoogle Scholar
• Cryer PE. Role of growth hormone in glucose counter-regulation. Horm Res. 1996;46:192–194.
   PubMedGoogle Scholar
• Vijayakumar A, Novosyadlyy R, Wu YJ, et al. Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res. 2010;20:1–7.
   PubMed Web of Science ®Google Scholar
• Frara S, Maffezzoni F, Mazziotti G, et al. Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab. 2016;27:470–483.
   PubMed Web of Science ®Google Scholar
• Olarescu NC, Bollerslev J. The impact of adipose tissue on insulin resistance in acromegaly. Trends Endocrinol Metab. 2016;27:226–237.
   PubMed Web of Science ®Google Scholar
• Hannon AM, Thompson CJ, Sherlock M. Diabetes in patients with acromegaly. Curr Diab Rep. 2017;17. DOI:10.1007/s11892-017-0838-7
   PubMed Web of Science ®Google Scholar
• Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human 1. Endocr Rev. 1998;19:717–797.
   PubMed Web of Science ®Google Scholar
• Møller N, Jørgensen JOL. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30:152–177.
   PubMed Web of Science ®Google Scholar
• Nielsen JH, Linde S, Welinder BS, et al. Growth hormone is a growth factor for the differentiated pancreatic β-cell. Mol Endocrinol. 1989;3:165–173.
   PubMedGoogle Scholar
• Nielsen S, Møller N, Christiansen JS, et al. Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure. Diabetes. 2001;50:2301–2308.
   PubMed Web of Science ®Google Scholar
• Dal J, List EO, Jørgensen JOL, et al. Glucose and fat metabolism in acromegaly: from mice models to patient care. Neuroendocrinology. 2016;103:96–105.
   PubMed Web of Science ®Google Scholar
• Karlander S, Vranić M, Efendić S. Increased glucose turnover and glucose cycling in acromegalic patients with normal glucose tolerance. Diabetologia. 1986;29:778–783.
   PubMed Web of Science ®Google Scholar
• Del Rincon J-P, Iida K, Gaylinn BD, et al. Growth hormone regulation of p85 expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes. 2007;56:1638–1646.
   PubMed Web of Science ®Google Scholar
• Olarescu NC, Ueland T, Godang K, et al. Inflammatory adipokines contribute to insulin resistance in active acromegaly and respond differently to different treatment modalities. Eur J Endocrinol. 2014;170:39–48.
   PubMed Web of Science ®Google Scholar
• Kasayama S, Otsuki M, Takagi M, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf). 2000;52:549–555.
   PubMed Web of Science ®Google Scholar
• Vila G, Jørgensen JOL, Luger A, et al. Insulin resistance in patients with acromegaly. Front Endocrinol (Lausanne). 2019;10. DOI:10.3389/fendo.2019.00509
   PubMed Web of Science ®Google Scholar
• Schalch DS, Turman NJ, Marcsisin VS, et al. Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus. J Clin Endocrinol Metab. 1993;77:1563–1568.
   PubMed Web of Science ®Google Scholar
• Moses AC, Young SCJ, Morrow LA, et al. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes. 1996;45:91–100.
   PubMed Web of Science ®Google Scholar
• Cusi K, DeFronzo R. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J Clin Endocrinol Metab. 2000;85:3077–3084.
   PubMed Web of Science ®Google Scholar
• Clemmons DR, Moses AC, Sommer A, et al. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res. 2005;15:265–274.
   PubMed Web of Science ®Google Scholar
• Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am. 2012;41:425–443.
   PubMed Web of Science ®Google Scholar
• Regazzo D, Barbot M, Scaroni C, et al. The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes. Rev Endocr Metab Disord. 2020;21:165–183.
   PubMed Web of Science ®Google Scholar
• Occhi G, Losa M, Albiger N, et al. The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells. J Neuroendocrinol. 2011;23:641–649.
   PubMed Web of Science ®Google Scholar
• Regazzo D, Losa M, Albiger NM, et al. The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp − somatotropinomas. Eur J Endocrinol. 2017;176:543–553.
   PubMed Web of Science ®Google Scholar
• Umahara M, Okada S, Ohshima K, et al. Glucose-dependent insulinotropic polypeptide induced growth hormone secretion in acromegaly. Endocr J. 2003;50:643–650.
   PubMed Web of Science ®Google Scholar
• Shekhawat VS, Bhansali S, Dutta P, et al. Glucose-dependent insulinotropic polypeptide (GIP) resistance and β-cell dysfunction contribute to hyperglycaemia in acromegaly. Sci Rep. 2019;9:5646.
   PubMed Web of Science ®Google Scholar
• Coculescu M, Niculescu D, Lichiardopol R, et al. Insulin resistance and insulin secretion in non-diabetic acromegalic patients. Exp Clin Endocrinol Diabetes. 2007;115:308–316.
   PubMed Web of Science ®Google Scholar
• Niculescu DA, Dusceac R, Caragheorgheopol A, et al. Disposition index in active acromegaly. Front Endocrinol (Lausanne). 2019;10:1–7.
   PubMed Web of Science ®Google Scholar
• Suda K, Matsumoto R, Fukuoka H, et al. The influence of type 2 diabetes on serum GH and IGF-I levels in hospitalized Japanese patients. Growth Horm IGF Res. 2016;29:4–10.
   PubMed Web of Science ®Google Scholar
• Dogansen S, Yalin G, Tanrikulu S, et al. Impact of glucose metabolism disorders on IGF-1 levels in patients with acromegaly. Horm Metab Res. 2018;50:408–413.
   PubMed Web of Science ®Google Scholar
• Cheng S, Gomez K, Serri O, et al. The role of diabetes in acromegaly associated neoplasia. PLoS One. 2015;10:1–9.
   Web of Science ®Google Scholar
• Sakai H, Tsuchiya K, Nakayama C, et al. Improvement of endothelial dysfunction in acromegaly after transsphenoidal surgery. Endocr J. 2008;55:853–859.
   PubMed Web of Science ®Google Scholar
• Kamenický P, Mazziotti G, Lombès M, et al. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev. 2014;35:234–281.
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Gola M, Bianchi A, et al. Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine. 2011;40:102–108.
   PubMed Web of Science ®Google Scholar
• Madeira M, Neto LV, de Paula Paranhos Neto F, et al. Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2013;98:1734–1741.
   PubMed Web of Science ®Google Scholar
• Maffezzoni F, Maddalo M, Frara S, et al. High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures. Endocrine. 2016;54:532–542.
   PubMed Web of Science ®Google Scholar
• Katznelson L, Laws ER, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933–3951.
   PubMed Web of Science ®Google Scholar
• Melmed S, Bronstein MD, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14:552–561.
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Galdiero M, et al. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab. 2009;94:3746–3756.
   PubMed Web of Science ®Google Scholar
• Tzanela M, Vassiliadi DA, Gavalas N, et al. Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin Endocrinol (Oxf). 2011;75:96–102.
   PubMed Web of Science ®Google Scholar
• Jonas C, Maiter D, Alexopoulou O. Evolution of glucose tolerance after treatment of acromegaly: a study in 57 patients. Horm Metab Res. 2016;48:299–305.
   PubMed Web of Science ®Google Scholar
• Ernaga Lorea A, Eguílaz Esparza N, Ollero García-Agulló MD, et al. Glucose metabolism before and after treatment in patients with acromegaly. Endocrinol Diabetes Nutr. 2017;64:363–368.
   PubMed Web of Science ®Google Scholar
• Kim SK, Suh S, Lee JI, et al. The ability of β-cells to compensate for insulin resistance is restored with a reduction in excess growth hormone in Korean acromegalic patients. J Korean Med Sci. 2012;27:177–183.
   PubMed Web of Science ®Google Scholar
• Stelmachowska-Banaś M, Zieliński G, Zdunowski P, et al. The impact of transsphenoidal surgery on glucose homeostasis and insulin resistance in acromegaly. Neurol Neurochir Pol. 2011;45:328–334.
   PubMed Web of Science ®Google Scholar
• Kinoshita Y, Fujii H, Takeshita A, et al. Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic β-cell function is preserved. Eur J Endocrinol. 2011;164:467–473.
   PubMed Web of Science ®Google Scholar
• Mori K, Iwasaki Y, Kawasaki-Ogita Y, et al. Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels. J Endocrinol Invest. 2013;36:853–859.
   PubMed Web of Science ®Google Scholar
• Dutta P, Hajela A, Gupta P, et al. The predictors of recovery from diabetes mellitus following neurosurgical treatment of acromegaly: a prospective study over a decade. Neurol India. 2019;67:757–762.
   PubMed Web of Science ®Google Scholar
• Wang Z, Gao L, Guo X, et al. Preoperative fasting C-peptide acts as a promising predictor of improved glucose tolerance in patients with acromegaly after transsphenoidal surgery: a retrospective study of 64 cases from a large pituitary center in China. Front Endocrinol (Lausanne). 2019;10:736.
   PubMed Web of Science ®Google Scholar
• Dorward NL. Endocrine outcomes in endoscopic pituitary surgery: a literature review. Acta Neurochir (Wien). 2010;152:1275–1279.
   PubMed Web of Science ®Google Scholar
• Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013;34:228–252.
   PubMed Web of Science ®Google Scholar
• Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine. 2003;20:255–264.
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10:243–248.
   PubMed Web of Science ®Google Scholar
• Giustina A, Barkan A, Beckers A, et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab. 2020;105:e937–46.
   Web of Science ®Google Scholar
• Parkinson C, Drake WM, Roberts ME, et al. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab. 2002;87:1797–1804.
   PubMed Web of Science ®Google Scholar
• James RA, Møller N, Chatterjee S, et al. Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide. Diabet Med. 1991;8:517–523.
   PubMed Web of Science ®Google Scholar
• Breidert M, Pinzer T, Wildbrett J, et al. Long-term effect of octreotide in acromegaly on insulin resistance. Horm Metab Res. 1995;27:226–230.
   PubMed Web of Science ®Google Scholar
• Arosio M, Macchelli S, Rossi CM, et al. Effects of treatment with octreotide in acromegalic patients - A multicenter Italian study. Eur J Endocrinol. 1995;133:430–439.
   PubMed Web of Science ®Google Scholar
• Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006;91:1397–1403.
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Porcelli T, Bogazzi F, et al. Effects of high-dose octreotide lar on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol. 2011;164:341–347.
   PubMed Web of Science ®Google Scholar
• Carmichael JD. Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits. Patient Prefer Adherence. 2012;6:73–82.
   PubMed Web of Science ®Google Scholar
• Díez JJ, Iglesias P, Gómez-Pan A. Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide. J Endocrinol Invest. 2001;24:303–309.
   PubMed Web of Science ®Google Scholar
• Gutt B, Bidlingmaier M, Kretschmar K, et al. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exp Clin Endocrinol Diabetes. 2005;113:139–144.
   PubMed Web of Science ®Google Scholar
• Steffin B, Gutt B, Bidlingmaier M, et al. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol. 2006;155:73–78.
   PubMed Web of Science ®Google Scholar
• Caron PJ, Petersenn S, Houchard A, et al. Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS study. Clin Endocrinol (Oxf). 2017;86:541–551.
   PubMed Web of Science ®Google Scholar
• Dal J, Høyer KL, Pedersen SB, et al. Growth hormone and insulin signaling in acromegaly: impact of surgery versus somatostatin analog treatment. J Clin Endocrinol Metab. 2016;101:3716–3723.
   PubMed Web of Science ®Google Scholar
• Ronchi C, Epaminonda P, Cappiello V, et al. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest. 2002;25:502–507.
   PubMed Web of Science ®Google Scholar
• Cambuli VM, Galdiero M, Mastinu M, et al. Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for growth hormone excess and for hyperglycemia. J Endocrinol Invest. 2012;35:154–159.
   PubMed Web of Science ®Google Scholar
• Baldelli R, Durante C, D’Amico E, et al. Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy. J Endocrinol Invest. 2003;26:1219–1224.
   PubMed Web of Science ®Google Scholar
• Shen M, Wang M, He W, et al. Impact of long-acting somatostatin analogues on glucose metabolism in acromegaly: a hospital-based study. Int J Endocrinol. 2018;2018:3015854.
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Savastano S, et al. Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study. J Clin Endocrinol Metab. 2009;94:2907–2914.
   PubMed Web of Science ®Google Scholar
• Sardella C, Cappellani D, Urbani C, et al. Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly. Eur J Endocrinol. 2016;175:443–453.
   PubMed Web of Science ®Google Scholar
• Cappellani D, Urbani C, Sardella C, et al. Diabetes mellitus induced by somatostatin analogue therapy is not permanent in acromegalic patients. Endocrinol Diabetes Metab. 2019;2:e00033.
   PubMedGoogle Scholar
• Colao A, Auriemma RS, Pivonello R, et al. Medical consequences of acromegaly: what are the effects of biochemical control? Rev Endocr Metab Disord. 2008;9:21–31.
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Floriani I, Bonadonna S, et al. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009;94:1500–1508.
   PubMed Web of Science ®Google Scholar
• Cozzolino A, Feola T, Simonelli I, et al. Somatostatin analogs and glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab. 2018;103:2089–2099.
   Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146:707–716.
   PubMed Web of Science ®Google Scholar
• Weckbecker G, Briner U, Lewis I, et al. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology. 2002;143:4123–4130.
   PubMed Web of Science ®Google Scholar
• Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology. 2004;80:47–50.
   PubMedGoogle Scholar
• Schmid HA, Brueggen J. Effects of somatostatin analogs on glucose homeostasis in rats. J Endocrinol. 2012;212:49–60.
   PubMed Web of Science ®Google Scholar
• Kumar U, Sasi R, Suresh S, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes. 1999;48:77–85.
   PubMed Web of Science ®Google Scholar
• Shenouda M, Maldonado M, Wang Y, et al. An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels. Am J Ther. 2014;21:164–173.
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99:791–799.
   PubMed Web of Science ®Google Scholar
• Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010;95:2781–2789.
   PubMed Web of Science ®Google Scholar
• Lacroix A, Gu F, Gallardo W, et al. Efficacy and safety of once-monthly pasireotide in Cushing’s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol. 2018;6:17–26.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): A randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:875–884.
   PubMed Web of Science ®Google Scholar
• Schmid HA, Brue T, Colao A, et al. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine. 2016;53:210–219.
   PubMed Web of Science ®Google Scholar
• Sheppard M, Bronstein MD, Freda P, et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary. 2015;18:385–394.
   PubMed Web of Science ®Google Scholar
• Bronstein MD, Fleseriu M, Neggers S, et al. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. BMC Endocr Disord. 2016;16:16.
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Rusch E, Geer EB. Safety and tolerability of pasireotide long-acting release in acromegaly—results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine. 2017;55:247–255.
   PubMed Web of Science ®Google Scholar
• Luger A. Hyperglycemia in pasireotide-treated patients with acromegaly and its treatment. Endocrine. 2016;54:0–1.
   Web of Science ®Google Scholar
• Gadelha M, Bex M, Colao A, et al. Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs. Front Endocrinol (Lausanne). 2020;10:1–10.
   Web of Science ®Google Scholar
• Gordon MB, Spiller KL. Pasireotide in an insulin-requiring diabetic acromegalic patient without worsening of hyperglycemia. Endocrinol Diabetes Metab Case Rep. 2017;2017:17-0003.
   Google Scholar
• Henry RR, Ciaraldi TP, Armstrong D, et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98:3446–3453.
   PubMed Web of Science ®Google Scholar
• Breitschaft A, Hu K, Hermosillo Reséndiz K, et al. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract. 2014;103:458–465.
   PubMed Web of Science ®Google Scholar
• Colao A, De Block C, Gaztambide MS, et al. Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary. 2014;17:180–186.
   PubMed Web of Science ®Google Scholar
• Silverstein JM. Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly. Pituitary. 2016;19:536–543.
   PubMed Web of Science ®Google Scholar
• Samson SL. Management of hyperglycemia in patients with acromegaly treated with pasireotide LAR. Drugs. 2016;76:1235–1243.
   PubMed Web of Science ®Google Scholar
• Liuzzi A, Chiodini PG, Botalla L, et al. Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration. J Clin Endocrinol Metab. 1974;38:910–912.
   PubMed Web of Science ®Google Scholar
• Sherlock M, Fernandez-Rodriguez E, Aragon-Alonso A, et al. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. J Clin Endocrinol Metab. 2009;94:1255–1263.
   PubMed Web of Science ®Google Scholar
• Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96:1327–1335.
   PubMed Web of Science ®Google Scholar
• Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23:1154–1161.
   PubMed Web of Science ®Google Scholar
• Tran L, Zielinski A, Roach AH, et al. Pharmacologic treatment of Type 2 diabetes. Ann Pharmacother. 2015;49:540–556.
   PubMedGoogle Scholar
• Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf. 2013;12:153–175.
   PubMed Web of Science ®Google Scholar
• Feek CM, Bevan JS, Taylor S, et al. The effect of bromocriptine on insulin secretion and glucose tolerance in patients with acromegaly. Clin Endocrinol (Oxf). 1981;15:473–478.
   PubMed Web of Science ®Google Scholar
• Rau H, Althoff PH, Schmidt K, et al. Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion. Clin Investig. 1993;71:372–378.
   PubMedGoogle Scholar
• Roemmler J, Steffin B, Gutt B, et al. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment. Growth Horm IGF Res. 2010;20:338–344.
   PubMed Web of Science ®Google Scholar
• Higham CE, Atkinson AB, Aylwin S, et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab. 2012;97:1187–1193.
   PubMed Web of Science ®Google Scholar
• Kopchick JJ, List EO, Kelder B, et al. Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications. Mol Cell Endocrinol. 2014;386:34–45.
   PubMed Web of Science ®Google Scholar
• Giustina A. Optimal use of pegvisomant in acromegaly: are we getting there? Endocrine. 2014;48:3–8.
   PubMed Web of Science ®Google Scholar
• Grottoli S, Maffei P, Bogazzi F, et al. ACROSTUDY: the Italian experience. Endocrine. 2014;48:334–341.
   PubMed Web of Science ®Google Scholar
• Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005;90:5684–5691.
   PubMed Web of Science ®Google Scholar
• Rose DR, Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res. 2002;12:418–424.
   PubMed Web of Science ®Google Scholar
• Higham CE, Rowles S, Russell-Jones D, et al. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J Clin Endocrinol Metab. 2009;94:2459–2463.
   PubMed Web of Science ®Google Scholar
• Lindberg-Larsen R, Møller N, Schmitz O, et al. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab. 2007;92:1724–1728.
   PubMed Web of Science ®Google Scholar
• Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol. 2007;156:75–82.
   PubMed Web of Science ®Google Scholar
• Droste M, Domberg J, Buchfelder M, et al. Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels. Eur J Endocrinol. 2014;171:59–68.
   PubMed Web of Science ®Google Scholar
• Urbani C, Sardella C, Calevro A, et al. Effects of medical therapies for acromegaly on glucose metabolism. Eur J Endocrinol. 2013;169:99–108.
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Ezzat S, D’Souza GA, et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf). 2009;71:549–557.
   PubMed Web of Science ®Google Scholar
• Madsen M, Poulsen PL, Ørskov H, et al. Cotreatment with pegvisomant and a Somatostatin Analog (SA) in SA-responsive acromegalic patients. J Clin Endocrinol Metab. 2011;96:2405–2413.
   PubMed Web of Science ®Google Scholar
• Jørgensen JOL, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab. 2005;90:5627–5631.
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol. 2006;154:467–477.
   PubMed Web of Science ®Google Scholar
• Drake WM, Rowles SV, Roberts ME, et al. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol. 2003;149:521–527.
   PubMed Web of Science ®Google Scholar
• De Marinis L, Bianchi A, Fusco A, et al. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary. 2007;10:227–232.
   PubMed Web of Science ®Google Scholar
• Feola T, Cozzolino A, Simonelli I, et al. Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab. 2019;104:2892–2902.
   PubMed Web of Science ®Google Scholar
• Störmann S, Schopohl J. Emerging drugs for acromegaly. Expert Opin Emerg Drugs. 2013;19:79–97.
   PubMed Web of Science ®Google Scholar
• Maffezzoni F, Frara S, Doga M, et al. New medical therapies of acromegaly. Growth Horm IGF Res. 2016;30–31:58–63.
   PubMed Web of Science ®Google Scholar
• Störmann S, Schopohl J. Perspectives on investigational drugs for acromegaly. Expert Opin Investig Drugs. 2016;25:381–384.
   PubMed Web of Science ®Google Scholar
• Lu M, Flanagan JU, Langley RJ, et al. Targeting growth hormone function: strategies and therapeutic applications. Signal Transduct Target Ther. 2019;4:3.
   PubMed Web of Science ®Google Scholar
• Gheorghiu ML, Negreanu F, Fleseriu M. Updates in the medical treatment of pituitary adenomas. Horm Metab Res. 2020;52:8–24.
   PubMed Web of Science ®Google Scholar
• Varlamov EV, McCartney S, Fleseriu M. Functioning pituitary adenomas – current treatment options and emerging medical therapies. Eur Endocrinol. 2019;15:30.
   PubMedGoogle Scholar
• Afargan M, Janson ET, Gelerman G, et al. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology. 2001;142:477–486.
   PubMed Web of Science ®Google Scholar
• Tarasco E, Seebeck P, Pfundstein S, et al. Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats. Endocrine. 2017;58:124–133.
   PubMed Web of Science ®Google Scholar
• Streuli J, Harris AG, Cottiny C, et al. Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors. Neuropeptides. 2018;68:84–89.
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Newell-price JDC, Ayuk J, et al. A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. Eur J Endocrinol. 2018 Aug;179(2):97-108.
   Google Scholar
• Madan A, Zhu YF, Markison S, et al. Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an orally bioavailable sst2-selective, nonpeptide somatostatin biased agonist, for the treatment of acromegaly: safety, pharmacokinetics, pharmacodynamics, and midazolam drug interact. J Endocr Soc. 2019;3:808.
   Google Scholar
• Adnan Z. Sodium glucose co-transporter inhibitors in patients with acromegaly and diabetes. Trends Endocrinol Metab. 2019;30:77–79.
   PubMed Web of Science ®Google Scholar
• Baroni MG, Giorgino F, Pezzino V, et al. Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing’s syndrome and acromegaly. Nutr Metab Cardiovasc Dis. 2016;26:85–102.
   PubMed Web of Science ®Google Scholar
• Warncke K, Kummer S, Kann PH, et al. Cardivascular risk profile in patients with diabetes and acromegaly or Cushing’s disease – analysis from the DPV database. Exp Clin Endocrinol Diabetes. 2020;128:104–110.
   PubMed Web of Science ®Google Scholar
• Kasuki L, Wildemberg LE, Gadelha MR. Personalized medicine in the treatment of acromegaly. Eur J Endocrinol. 2018;178(3):R89-R100.
   Google Scholar
• Coopmans EC, Muhammad A, van der Lely AJ, et al. How to position pasireotide LAR treatment in acromegaly. J Clin Endocrinol Metab. 2019;104:1978–1988.
   PubMed Web of Science ®Google Scholar
• Coopmans EC, van Meyel SWF, van der Lely AJ, et al. The position of combined medical treatment in acromegaly. Arch Endocrinol Metab. 2020;63:646–652.
   Web of Science ®Google Scholar